Lasolvan Rino - spray from nasal congestion 10 ml
Transparent, pale yellow solution with the smell of eucalyptus. Pharmacological action The active substance of LAZOLVAN ® RINO is tramazoline hydrochloride, alpha-2-adrenomimetic, causes vasoconstriction.
When applied to the mucous membranes of the nose due to the vasoconstrictor effect, the drug reduces swelling.
As a result, the patency of the nasal passages is quickly restored, nasal breathing is facilitated for a long time.
The action of the drug begins within the first 5 minutes and lasts 8-10 hours.
Pharmacokinetics
Pharmacinetic studies in humans have not been conducted.
The pharmacokinetics of tramazolin have been studied in rats, rabbits and monkeys.
It has been shown that after administration of the drug inside or intranasally, 50-80% of the administered dose is absorbed.
Tramazoline and its metabolites are distributed in all internal organs, the highest concentration is consistently found in the liver.
After oral or topical administration, the main metabolites are determined in the urine.
The terminal half-life is 5 to 7 hours.
Name ENG
Lasolvan rhino
Clinical and pharmacological group
Decongestant drug - alpha-adrenergic agonist
ATX code
R01AA09
Dosage
tramazoline hydrochloride monohydrate in terms of tramazoline hydrochloride 82 μg.
Structure
1 spray dose contains:
Active substance:
tramazoline hydrochloride monohydrate in terms of tramazoline hydrochloride 82 μg.
Excipients:
citric acid monohydrate 270 mcg, sodium hydroxide 154 mcg, benzalkonium chloride
14 mcg, hypromellose (hydroxypropyl methylcellulose) 35 mcg, povidone 2101 mcg,
glycerol 85% 700 mcg, magnesium sulfate heptahydrate 49 mcg, magnesium chloride
hexahydrate 35 μg, calcium chloride dihydrate 11 μg, sodium bicarbonate 1 μg,
sodium chloride 183 mcg, cineole (eucalyptol) 7 mcg, L-menthol (levomenthol) 14 mcg,
racemic camphor 14 mcg, purified water 66 358 mcg.
Indications
Swelling of the nasal mucosa, nasal congestion caused by acute
respiratory diseases and / or hay fever (rhinitis, hay fever)
sinusitis and otitis media (eustachitis) to facilitate the outflow of the contents of the accessory
sinuses, as recommended by a doctor.
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
Contraindications
Hypersensitivity to tramazoline hydrochloride or benzalkonium
hydrochloride, as well as to other components of the drug, angle-closure glaucoma,
atrophic rhinitis, operations on the skull, carried out through the nasal cavity, in
anamnesis, children under 6 years of age.
INN / Active ingredient
tramazoline hydrochloride monohydrate
Specifications
Category
Runny nose
Scope of the medicinal product
Respiratory system
Release form
Spray
Manufacturer country
Italy
Package quantity, pcs
one
Scope of application
Virology
Minimum age from
6 years
Way of introduction
Through the respiratory tract
Vacation conditions
Without recipe
Volume, ml.
10 ml
Brand name
Sanofi
The amount of the dosage form in the primary package
10 ml
Primary packaging type
Bottle
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
Decongestant - alpha adrenergic agonist
Anatomical and therapeutic characteristics
R01AA09 Tramazoline
Dosage form
Dosed nasal spray
Expiration date in days
1095
The target audience
Children
Package weight, g
35
Mode of application
:
Adults and children from 6 years of age: 1 injection in each nasal passage.
Up to 4 injections in each nasal passage a day.
Do not use the drug for more than 5-7 days without a doctor's prescription.
Dosage (volume) of the substance in the preparation
:
tramazoline hydrochloride monohydrate in terms of tramazoline hydrochloride - 82 mcg